LDXHF (Lumos Diagnostics Holdings) EBIT: $-8.71 Mil (TTM As of Dec. 2025)


LDXHF Lumos Diagnostics Holdings Ltd LDXHF
31 GF Score
Price $0.08
GF Value $0.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lumos Diagnostics Holdings EBIT?

Lumos Diagnostics Holdings LDXHF 31 EBIT is $-8.71 Mil as of Dec. 2025. GuruFocus rates LDXHF with a GF Score™ of 31/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Lumos Diagnostics Holdings's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $-4.05 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.71 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Lumos Diagnostics Holdings's annualized ROC % for the quarter that ended in Dec. 2025 was -63.90%. Lumos Diagnostics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -136.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Lumos Diagnostics Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -13.03%.

Lumos Diagnostics Holdings  (OTCPK:LDXHF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Lumos Diagnostics Holdings's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-13.02 * ( 1 - 0% )/( (20.147 + 20.602)/ 2 )
=-13.02/20.3745
=-63.90 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=20.812 - 2.919 - ( 1.956 - max(0, 8.715 - 6.461+1.956))
=20.147

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21.103 - 3.342 - ( 2.994 - max(0, 10.497 - 7.656+2.994))
=20.602

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Lumos Diagnostics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.094/( ( (6.169 + max(-3.165, 0)) + (5.73 + max(-4.739, 0)) )/ 2 )
=-8.094/( ( 6.169 + 5.73 )/ 2 )
=-8.094/5.9495
=-136.05 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.045 + 0.521 + 2.939) - (2.919 + 0 + 4.751)
=-3.165

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.007 + 1.064 + 1.591) - (3.342 + 0 + 6.059)
=-4.739

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Lumos Diagnostics Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-8.706/66.793
=-13.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings EBIT Related Terms

Lumos Diagnostics Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Lumos Diagnostics Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings EBIT Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24 Jun25
EBIT
-45.55 -8.60 -8.09 -7.16

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.61 -2.47 -2.50 -4.66 -4.05

LDXHF vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Lumos Diagnostics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Diagnostics Holdings EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lumos Diagnostics Holdings's EV-to-EBIT falls into.


LDXHF
31GF Score
Lumos Diagnostics Holdings Ltd LDXHF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumos Diagnostics Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-8.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-8.71 Mil mean?
Lumos Diagnostics Holdings (LDXHF) has a EBIT of $-8.71 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lumos Diagnostics Holdings.
Is Lumos Diagnostics Holdings' EBIT too high?
Lumos Diagnostics Holdings' current EBIT is $-8.71 Mil. Overall, Lumos Diagnostics Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' EBIT compare to ABT and SYK?
Lumos Diagnostics Holdings' EBIT of $-8.71 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lumos Diagnostics Holdings. Lumos Diagnostics Holdings's current EBIT is $-8.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (LDXHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.08 — trading 300% above its estimated fair value. The current EBIT is $-8.71 Mil. Lumos Diagnostics Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Lumos Diagnostics Holdings (LDXHF), the current EBIT is $-8.71 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumos Diagnostics Holdings (LDXHF) Overvalued in 2026?

Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued. The current stock price of $0.08 is trading 300% above its estimated GF Value™ of $0.02. GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.

Key valuation signals for LDXHF:

  • EBIT: $-8.71 Mil
  • GF Value™: $0.02 vs. price of $0.08 (300% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the LDXHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumos Diagnostics Holdings Business Description

Other Exchanges LDX:Australia
Address 2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
31GF Score

Get the complete analysis for LDXHF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price
$0.02
GF Value